Cargando…

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Zongyi, Zhou, Yuxin, Wang, Rongjie, Wang, Jin, Chen, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781707/
https://www.ncbi.nlm.nih.gov/pubmed/36559056
http://dx.doi.org/10.3390/pharmaceutics14122561
_version_ 1784857140261814272
author Wei, Zongyi
Zhou, Yuxin
Wang, Rongjie
Wang, Jin
Chen, Zhenhua
author_facet Wei, Zongyi
Zhou, Yuxin
Wang, Rongjie
Wang, Jin
Chen, Zhenhua
author_sort Wei, Zongyi
collection PubMed
description Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system is usually composed of a nanocarrier and a targeting component. The targeting component is called a “ligand”. Aptamers have high target affinity and specificity, which are identified as attractive and promising ligands. Therefore, aptamers have potential application in the development of smart targeting systems. For instance, aptamers are able to efficiently recognize tumor markers such as nucleolin, mucin, and epidermal growth factor receptor (EGFR). Besides, aptamers can also identify glycoproteins on the surface of tumor cells. Thus, the aptamer-mediated targeted drug delivery system has received extensive attention in the application of cancer therapy. This article reviews the application of aptamers as smart ligands for targeted drug delivery in cancer therapy. Special interest is focused on aptamers as smart ligands, aptamer-conjugated nanocarriers, aptamer targeting strategy for tumor microenvironment (TME), and aptamers that are specified to crucial cancer biomarkers for targeted drug delivery.
format Online
Article
Text
id pubmed-9781707
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97817072022-12-24 Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy Wei, Zongyi Zhou, Yuxin Wang, Rongjie Wang, Jin Chen, Zhenhua Pharmaceutics Review Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system is usually composed of a nanocarrier and a targeting component. The targeting component is called a “ligand”. Aptamers have high target affinity and specificity, which are identified as attractive and promising ligands. Therefore, aptamers have potential application in the development of smart targeting systems. For instance, aptamers are able to efficiently recognize tumor markers such as nucleolin, mucin, and epidermal growth factor receptor (EGFR). Besides, aptamers can also identify glycoproteins on the surface of tumor cells. Thus, the aptamer-mediated targeted drug delivery system has received extensive attention in the application of cancer therapy. This article reviews the application of aptamers as smart ligands for targeted drug delivery in cancer therapy. Special interest is focused on aptamers as smart ligands, aptamer-conjugated nanocarriers, aptamer targeting strategy for tumor microenvironment (TME), and aptamers that are specified to crucial cancer biomarkers for targeted drug delivery. MDPI 2022-11-22 /pmc/articles/PMC9781707/ /pubmed/36559056 http://dx.doi.org/10.3390/pharmaceutics14122561 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wei, Zongyi
Zhou, Yuxin
Wang, Rongjie
Wang, Jin
Chen, Zhenhua
Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy
title Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy
title_full Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy
title_fullStr Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy
title_full_unstemmed Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy
title_short Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy
title_sort aptamers as smart ligands for targeted drug delivery in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781707/
https://www.ncbi.nlm.nih.gov/pubmed/36559056
http://dx.doi.org/10.3390/pharmaceutics14122561
work_keys_str_mv AT weizongyi aptamersassmartligandsfortargeteddrugdeliveryincancertherapy
AT zhouyuxin aptamersassmartligandsfortargeteddrugdeliveryincancertherapy
AT wangrongjie aptamersassmartligandsfortargeteddrugdeliveryincancertherapy
AT wangjin aptamersassmartligandsfortargeteddrugdeliveryincancertherapy
AT chenzhenhua aptamersassmartligandsfortargeteddrugdeliveryincancertherapy